Active Biotech AB (publ) (STO:ACTI)
Sweden · Delayed Price · Currency is SEK | Market Cap | 105.44M +14.3% |
| Revenue (ttm) | n/a |
| Net Income | -33.52M |
| EPS | -1.79 |
| Shares Out | 26.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,768 |
| Open | 4.020 |
| Previous Close | 3.995 |
| Day's Range | 4.000 - 4.100 |
| 52-Week Range | 3.100 - 9.500 |
| Beta | 1.44 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The ... [Read more]
Financial Performance
Financial StatementsNews
Active Biotech AB Quarterly report: Q2 2026
Active Biotech AB has published its Q2 2026 quarterly earnings report on August 20, 2026.
Active Biotech AB Slides: Company presentation
Active Biotech AB has posted slides in relation to its latest quarterly earnings report, which was published on July 3, 2026.
Active Biotech AB Quarterly report: Q1 2026
Active Biotech AB has published its Q1 2026 quarterly earnings report on May 7, 2026.
Active Biotech AB Slides: Company presentation
Active Biotech AB has posted slides in relation to its latest quarterly earnings report, which was published on April 21, 2026.
Active Biotech AB Slides: Company presentation
Active Biotech AB has posted slides in relation to its latest quarterly earnings report, which was published on March 25, 2026.
Active Biotech AB Annual report: Q4 2025
Active Biotech AB has published its Q4 2025 annual report on February 12, 2026.
Active Biotech AB Quarterly report: Q4 2025
Active Biotech AB has published its Q4 2025 quarterly earnings report on February 12, 2026.
Active Biotech AB: Active Biotech's patent related to a pharmaceutical formulation of tasquinimod will be granted in the US
Lund, November 25, 2025, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent and Trademark Office (USPTO) has issued a notification that the company's patent application rela...
Active Biotech AB Slides: Company Presentation
Active Biotech AB has posted slides in relation to its latest quarterly earnings report, which was published on November 6, 2025.
Active Biotech AB Quarterly report: Q3 2025
Active Biotech AB has published its Q3 2025 quarterly earnings report on November 6, 2025.